Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512916 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL8764356 | 0.83 | PTGS2 (0.53) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6513085 | 0.82 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL6531156 | 0.82 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL8765035 | 0.78 | PTGS2 (0.62) | PTGS2PTGS1 | |
| SCHEMBL1245336 | 0.77 | KMT2A (0.62) | PTGS2PTGS1 | |
| SCHEMBL6352457 | 0.75 | PTGS2 (0.77) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL9200927 | 0.73 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL8764591 | 0.72 | PTGS2 (0.64) | PTGS2PTGS1CA1CA2CA4 | |
| SCHEMBL6517842 | 0.71 | PTGS2 (0.71) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | PFIZER INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157824-A1 | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents | CNR1, PTGS1, PTGER1 | PTGS2 29/4885PTGS1 2/4885CA1 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.